What's Happening?
The U.S. Department of Justice (DOJ) and the Department of Health and Human Services (HHS) have jointly launched a new six-month pilot program aimed at health care companies. This program, initiated on October 22, 2026, allows companies to self-disclose
previously unknown potential violations of the False Claims Act (FCA) and receive a coordinated civil release. Under this Self-Disclosure Pilot Program (SDPP), participating companies can avoid factual admissions, Corporate Integrity Agreements from the HHS Office of the Inspector General, and civil monetary penalties or Medicare enrollment revocation from the Centers for Medicare & Medicaid Services. The repayment amount for disclosed violations will be calculated by DOJ's Civil Division, ranging from 1.25 to 1.6 times the 'Base Self-Disclosure Repayment,' depending on factors such as disclosure timeliness, misconduct duration, senior leadership involvement, financial benefits, and remediation efforts. The SDPP specifically covers civil conduct related to HHS federal health care programs and requires disclosures to be submitted by April 22, 2027.
Why It's Important?
This pilot program represents a significant shift in how the federal government addresses potential False Claims Act violations within the health care sector. By offering a structured path for self-disclosure with predictable terms, the DOJ and HHS aim to encourage companies to proactively report misconduct rather than waiting for government investigations or whistleblower actions. This could lead to faster resolution of cases, recovery of funds, and reduced litigation costs for both the government and health care entities. For health care companies, the SDPP provides an incentive to review their compliance programs thoroughly and report any discovered issues, potentially avoiding more severe penalties and reputational damage associated with traditional enforcement actions. The program's focus on civil liability also clarifies the distinction between civil and criminal conduct, directing criminal matters to DOJ's National Fraud Enforcement Division.
What's Next?
Health care entities operating within HHS federal health care programs have until April 22, 2027, to submit self-disclosures under the SDPP. Companies are expected to analyze their internal investigations and potential noncompliance to determine if participation in this program is warranted. Submissions must detail the violative conduct, provide supporting documents, outline corrective actions, and include financial information for repayment calculation. Following the deadline, the DOJ and HHS will assess the effectiveness of the pilot program. The success of the SDPP, measured by the number of disclosures and the efficiency of resolutions, could influence whether it becomes a permanent fixture in federal enforcement policy. Companies that do not participate but later face FCA allegations may find themselves subject to traditional enforcement mechanisms, which typically involve higher penalties and more stringent oversight.
Beyond the Headlines
The SDPP reflects a broader trend in regulatory enforcement towards encouraging corporate self-policing and cooperation. By offering tangible benefits for voluntary disclosure, the government aims to foster a culture of compliance within the health care industry. However, this program also presents a complex decision for companies: weighing the benefits of reduced penalties against the potential for uncovering previously unknown liabilities. The program's success will depend on companies' trust in the government's commitment to the outlined terms and the perceived fairness of the repayment multiplier. Furthermore, the SDPP could indirectly influence the whistleblower landscape, as companies might be more inclined to self-disclose before a relator brings a qui tam action. This initiative could set a precedent for similar self-disclosure programs in other regulated industries, signaling a strategic shift in how federal agencies approach corporate accountability.













